When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
On March 1, Morphic Holding 's (NASDAQ: MORF) stock more than doubled after the company announced interim phase 1 data on its experimental therapy, MORF-057. That's a pretty significant pop for an under-the-radar biotech, especially based on data that comes from so early in a drug's clinical trial process.
Since then, the stock has sold off by nearly 33% from its highs. Can investors trust this biotech, which has no products on the market?